Epicutaneous immunotherapy for food allergy as a novel pathway for oral tolerance induction

Immunotherapy

Volumn 7, Issue 12, 2015, Pages 1293-1305

  Mondoulet, Lucie ^a   Dioszeghy, Vincent ^a   Thébault, Claude ^a   Benhamou, Pierre Henri ^a   Dupont, Christophe ^b  

^a DBV TECHNOLOGIES   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

adults; animal models; children; epicutaneous immunotherapy; food allergy; regulatory T cells; skin

Indexed keywords

CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); CYTOKINE RELEASE; DESENSITIZATION; DNA MODIFICATION; EPICUTANEOUS IMMUNOTHERAPY; EPIDERMIS; EPIGENETICS; FOLLOW UP; FOOD ALLERGY; HUMAN; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MILK ALLERGY; NONHUMAN; PATIENT SAFETY; PEANUT ALLERGY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SKIN; SKIN INTEGRITY; STRATUM CORNEUM; TH1 CELL; TH2 CELL; TRANSDERMAL PATCH; ADOLESCENT; ANIMAL; CHILD; DEVICES; DISEASE MODEL; EXPERIMENTAL THERAPY; GENETIC EPIGENESIS; IMMUNOLOGY; INFANT; INTRADERMAL DRUG ADMINISTRATION; MILK HYPERSENSITIVITY; MOUSE; PEANUT HYPERSENSITIVITY; PRESCHOOL CHILD; PROCEDURES;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ANIMALS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DESENSITIZATION, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; EPIGENESIS, GENETIC; HUMANS; INFANT; MICE; MILK HYPERSENSITIVITY; PEANUT HYPERSENSITIVITY; SKIN; T-LYMPHOCYTES, REGULATORY; THERAPIES, INVESTIGATIONAL; TRANSDERMAL PATCH;

EID: 84948985571     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.15.86     Document Type: Review

References (95)

1. Pratico AD, Leonardi S. Immunotherapy for food allergies: a myth or a reality Immunotherapy 7(2), 147-161 (2015).
2. Spergel JM, Mizoguchi E, Brewer JPet al.Epicutaneous sensitization with protein antigen induces localized allergic dermatitis and hyperresponsiveness to methacholine after single exposure to aerosolized antigen in mice. J. Clin. Invest. 101(8), 1614-1622 (1998).
3. Lack G, Fox D, Northstone K, Golding J. Factors associated with the development of peanut allergy in childhood. N. Engl. J. Med. 348(11), 977-985 (2003).
4. Strid J, Hourihane J, Kimber I et al.Epicutaneous exposure to peanut protein prevents oral tolerance and enhances allergic sensitization. Clin. Exp. Allergy 35(6), 757-766 (2005).
5. Strid J, Callard R, Strobel S. Epicutaneous immunization converts subsequent and established antigen-specific T helper type 1 (Th1) to Th2-type responses. Immunology 119(1), 27-35 (2006).
6. Fox AT, Sasieni P, Du TG et al. Household peanut consumption as a risk factor for the development of peanut allergy. J. Allergy Clin. Immunol. 123(2), 417-423 (2009).
7. Deacock SJ. An approach to the patient with urticaria. Clin. Exp. Immunol. 153(2), 151-161 (2008).
8. Werfel T. Skin manifestations in food allergy. Allergy 56(Suppl. 67), 98-101 (2001).
9. Charlesworth EN. The allergy and immunology specialist: what is the role in the treatment of skin disease Clin. Rev. Allergy Immunol. 27(2), 123-132 (2004).
10. Wollenberg A, Feichtner K. Atopic dermatitis and skin allergies-update and outlook. Allergy 68(12), 1509-1519 (2013).
11. Brough HA, Liu AH, Sicherer S et al. Atopic dermatitis increases the effect of exposure to peanut antigen in dust on peanut sensitization and likely peanut allergy. J. Allergy Clin. Immunol. 135(1), 164-170 (2015).
12. Hauk PJ. The role of food allergy in atopic dermatitis. Curr. Allergy Asthma Rep. 8(3), 188-194 (2008).
13. Jones SM, Burks AW, Dupont C. State of the art on food allergen immunotherapy: oral, sublingual, and epicutaneous. J. Allergy Clin. Immunol. 133(2), 318-323 (2014).
14. Durham SR, Walker SM, Varga EM et al. Longterm clinical efficacy of grass-pollen immunotherapy. N. Engl. J. Med. 341(7), 468-475 (1999).
15. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J. Allergy Clin. Immunol. 102(4 Pt 1), 558-562 (1998).
16. Pajno GB, Barberio G, De LF et al. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin. Exp. Allergy 31(9), 1392-1397 (2001).
17. Moller C, Dreborg S, Ferdousi HA et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J. Allergy Clin. Immunol. 109(2), 251-256 (2002).
18. Pautrizel R, Cabanieu G, Bricaud H, Broustet P. Allergenic group specificity & therapeutic consequences in asthma; specific desensitization method by epicutaneous route. Sem. Hop. 33(22), 1394-1403 (1957).
19. Blamoutier P, Blamoutier J, Guibert L. Treatment of pollinosis with pollen extracts by the method of cutaneous quadrille ruling. Presse Med. 67, 2299-2301 (1959).
20. Eichenberger H, Storck H. Co-seasonal desensitization of pollinosis with the scarification-method of Blamoutier. Acta Allergol. 21(3), 261-267 (1966).
21. Rostenberg A, Sulzberger MB. Some results of patch tests: a compilation and discussion of cutaneous reactions to about five hundred different substances, as elicited by over ten thousand tests in approximately one thousand patients. Arch. Dermatol. Syphilol. 35(3), 433-454 (1937).
22. Mitchell EB, Crow J, Chapman MDet al.Basophils in allergen-induced patch test sites in atopic dermatitis. Lancet 1(8264), 127-130 (1982).
23. Ring J, Darsow U, Gfesser M, Vieluf D. The 'atopy patch test'in evaluating the role of aeroallergens in atopic eczema. Int. Arch. Allergy Immunol. 113(1-3), 379-383 (1997).
24. Isolauri E, Turjanmaa K. Combined skin prick and patch testing enhances identification of food allergy in infants with atopic dermatitis. J. Allergy Clin. Immunol. 97(1 Pt 1), 9-15 (1996).
25. De Boissieu D, Waguet JC, Dupont C. The atopy patch tests for detection of cow's milk allergy with digestive symptoms. J. Pediatr. 142(2), 203-205 (2003).
26. Kalach N, Soulaines P, de BD, Dupont C. A pilot study of the usefulness and safety of a ready-to-use atopy patch test (Diallertest) versus a comparator (Finn Chamber) during cow's milk allergy in children. J. Allergy Clin. Immunol. 116(6), 1321-1326 (2005).
27. Dupont C, Kalach N, Soulaines Pet al.Cow's milk epicutaneous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity. J. Allergy Clin. Immunol. 125(5), 1165-1167 (2010).
28. Nelson HS, Lahr J, Rule R et al.Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J. Allergy Clin. Immunol. 99(6 Pt 1), 744-751 (1997).
29. Hofmann AM, Scurlock AM, Jones SM et al. Safety of a peanut oral immunotherapy protocol in children with peanut allergy. J. Allergy Clin. Immunol. 124(2), 286-291 (2009).
30. Blumchen K, Ulbricht H, Staden U et al. Oral peanut immunotherapy in children with peanut anaphylaxis. J. Allergy Clin. Immunol. 126(1), 83-91 (2010).
31. Varshney P, Jones SM, Scurlock AM et al. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J. Allergy Clin. Immunol. 127(3), 654-660 (2011).
32. Wasserman RL, Factor JM, Baker JW et al. Oral immunotherapy for peanut allergy: multipractice experience with epinephrine-treated reactions. J. Allergy Clin. Immunol. Pract. 2(1), 91-96 (2014).
33. Mempel M, Rakoski J, Ring J, Ollert M. Severe anaphylaxis to kiwi fruit: immunologic changes related to successful sublingual allergen immunotherapy. J. Allergy Clin. Immunol. 111(6), 1406-1409 (2003).
34. De Boissieu D, Dupont C. Sublingual immunotherapy for cow's milk protein allergy: a preliminary report. Allergy 61(10), 1238-1239 (2006).
35. Fleischer DM, Burks AW, Vickery BP et al. Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial. J. Allergy Clin. Immunol. 131(1), 119-127 (2013).
36. Chin SJ, Vickery BP, Kulis MD et al. Sublingual versus oral immunotherapy for peanut-allergic children: a retrospective comparison. J. Allergy Clin. Immunol. 132(2), 476-478 (2013).
37. Keet CA, Frischmeyer-Guerrerio PA, Thyagarajan A et al. The safety and efficacy of sublingual and oral immunotherapy for milk allergy. J. Allergy Clin. Immunol. 129(2), 448-455, 455 (2012).
38. Burks AW, Wood RA, Jones SM et al. Sublingual immunotherapy for peanut allergy: long-term follow-up of a randomized multicenter trial. J. Allergy Clin. Immunol. 135(5), 1240-1248 (2015).
39. Marogna M, Spadolini I, Massolo A et al. Longlasting effects of sublingual immunotherapy according to its duration: a 15 year prospective study. J. Allergy Clin. Immunol. 126(5), 969-975 (2010).
40. Bauch C, Kolle SN, Fabian E et al. Intralaboratory validation of four in vitro assays for the prediction of the skin sensitizing potential of chemicals. Toxicol. In Vitro 25(6), 1162-1168 (2011).
41. Senti G, Graf N, Haug S et al. Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. J. Allergy Clin. Immunol. 124(5), 997-1002 (2009).
42. Senti G, von MS, Kundig TM. Epicutaneous immunotherapy for aeroallergen and food allergy. Curr. Treat. Options Allergy 1, 68-78, eCollection 2014 (2013).
43. Senti G, von MS, Kundig TM. Epicutaneous allergen administration: is this the future of allergen-specific immunotherapy Allergy 66(6), 798-809 (2011).
44. Senti G, von MS, Tay F et al. Determinants of efficacy and safety in epicutaneous allergen immunotherapy: summary of three clinical trials. Allergy 70(6), 707-771 (2015).
45. Senti G, von MS, Tay F et al. Epicutaneous allergenspecific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: a double-blind, placebo-controlled dose escalation study. J. Allergy Clin. Immunol. 129(1), 128-135 (2012).
46. Dickel H, Goulioumis A, Gambichler T et al. Standardized tape stripping: a practical and reproducible protocol to uniformly reduce the stratum corneum. Skin Pharmacol. Physiol. 23(5), 259-265 (2010).
47. Dickel H, Gambichler T, Kamphowe J et al. Standardized tape stripping prior to patch testing induces upregulation of Hsp90, Hsp70, IL-33, TNF-alpha and IL-8/CXCL8 mRNA: new insights into the involvement of 'alarmins'. Contact Dermatitis 63(4), 215-222 (2010).
48. Nickoloff BJ, Naidu Y. Perturbation of epidermal barrier function correlates with initiation of cytokine cascade in human skin. J. Am. Acad. Dermatol. 30(4), 535-546 (1994).
49. Agbotounou W, Martin L, Dupont B et al. Epicutaneous Immunotherapy (EPIT) is safe for the treatment of peanut allergy in allergic patients. J. Allergy Clin. Immunol. 131(2), Abstract 91 (2013).
50. Dupont C, Bourrier T, De Blay F et al. Peanut Epicutaneous Immunotherapy (EPIT) in peanut-allergic children: 18 months treatment in The Arachild study. J. Allergy Clin. Immunol. 133(2), Abstract 102 (2014).
51. Sampson HA, Agbotounou W, Thébault C et al. Epicutaneous Immunotherapy (EPIT) is effective and safe to treat peanut allergy: a multi-national doubleblind placebo-controlled randomized Phase IIb trial. J. Allergy Clin. Immunol. 135(2), AB390 (2015).
52. Mondoulet L, Dioszeghy V, Ligouis M et al.Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergy. Clin. Exp. Allergy 40(4), 659-667 (2010).
53. Mondoulet L, Dioszeghy V, Vanoirbeek JA et al.Epicutaneous immunotherapy using a new epicutaneous delivery system in mice sensitized to peanuts. Int. Arch. Allergy Immunol. 154(4), 299-309 (2011).
54. Dioszeghy V, Mondoulet L, Dhelft V et al. Epicutaneous immunotherapy results in rapid allergen uptake by dendritic cells through intact skin and downregulates the allergenspecific response in sensitized mice. J. Immunol. 186(10), 5629-5637 (2011).
55. Mondoulet L, Dioszeghy V, Larcher T et al. Epicutaneous immunotherapy (EPIT) blocks the allergic esophago-gastroenteropathy induced by sustained oral exposure to peanuts in sensitized mice. PLoS ONE 7(2), e31967 (2012).
56. Mondoulet L, Dioszeghy V, Puteaux E et al. Intact skin and not stripped skin is crucial for the safety and efficacy of peanut epicutaneous immunotherapy (EPIT) in mice. Clin. Transl. Allergy 2(1), 22 (2012).
57. Hill DJ, Hosking CS. Food allergy and atopic dermatitis in infancy: an epidemiologic study. Pediatr. Allergy Immunol. 15(5), 421-427 (2004).
58. Lack G. Epidemiologic risks for food allergy. J. Allergy Clin. Immunol. 121(6), 1331-1336 (2008).
59. Strid J, Thomson M, Hourihane J et al. A novel model of sensitization and oral tolerance to peanut protein. Immunology 113(3), 293-303 (2004).
60. Strid J, Strobel S. Skin barrier dysfunction and systemic sensitization to allergens through the skin. Curr. Drug Targets Inflamm. Allergy 4(5), 531-541 (2005).
61. Dunkin D, Berin MC, Mayer L. Allergic sensitization can be induced via multiple physiologic routes in an adjuvantdependent manner. J. Allergy Clin. Immunol. 128(6), 1251-1258 (2011).
62. Kondo H, Ichikawa Y, Imokawa G. Percutaneous sensitization with allergens through barrier-disrupted skin elicits a Th2-dominant cytokine response. Eur. J. Immunol. 28(3), 769-779 (1998).
63. Egbuniwe IU, Karagiannis SN, Nestle FO, Lacy KE. Revisiting the role of B cells in skin immune surveillance. Trends Immunol. 36(2), 102-111 (2015).
64. Strid J, Tigelaar RE, Hayday AC. Skin immune surveillance by T cells-A new order Semin. Immunol. 21(3), 110-120 (2009).
65. Tokura Y, Kobayashi M, Kabashima K. Epidermal chemokines and modulation by antihistamines, antibiotics and antifungals. Exp. Dermatol. 17(2), 81-90 (2008).
66. Chavanas S, Bodemer C, Rochat A et al. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat. Genet. 25(2), 141-142 (2000).
67. Palmer CN, Irvine AD, Terron-Kwiatkowski A et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat. Genet. 38(4), 441-446 (2006).
68. Thyssen JP, Kezic S. Causes of epidermal filaggrin reduction and their role in the pathogenesis of atopic dermatitis. J. Allergy Clin. Immunol. 134(4), 792-799 (2014).
69. Thyssen JP, Tang L, Husemoen LL et al. Filaggrin gene mutations are not associated with food and aeroallergen sensitization without concomitant atopic dermatitis in adults. J. Allergy Clin. Immunol. 15, 10 (2015).
70. Brown SJ, Asai Y, Cordell HJ et al. Loss-of-function variants in the filaggrin gene are a significant risk factor for peanut allergy. J. Allergy Clin. Immunol. 127(3), 661-667 (2011).
71. Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. N. Engl. J. Med. 365(14), 1315-1327 (2011).
72. Brough HA, Simpson A, Makinson K et al. Peanut allergy: effect of environmental peanut exposure in children with filaggrin loss-of-function mutations. J. Allergy Clin. Immunol. 134(4), 867-875 (2014).
73. Venkataraman D, Soto-Ramirez N, Kurukulaaratchy RJ et al. Filaggrin loss-of-function mutations are associated with food allergy in childhood and adolescence. J. Allergy Clin. Immunol. 134(4), 876-882 (2014).
74. Heimall J, Spergel JM. Filaggrin mutations and atopy: consequences for future therapeutics. Expert. Rev Clin. Immunol. 8(2), 189-197 (2012).
75. Maurer D, Stingl G. Langerhans cells. In: Dentritic cells. Lotze MT, Thomson AW (Eds). 35-50 (2011). http://store.elsevier.com 76
76. Henri S, Guilliams M, Poulin LF et al. Disentangling the complexity of the skin dendritic cell network. Immunol. Cell. Biol. 88(4), 366-375 (2010).
77. Guilliams M, Henri S, Tamoutounour S et al. From skin dendritic cells to a simplified classification of human and mouse dendritic cell subsets. Eur. J. Immunol. 40(8), 2089-2094 (2010).
78. Ochoa MT, Loncaric A, Krutzik SR et al. "Dermal dendritic cells" comprise two distinct populations: CD1+ dendritic cells and CD209+ macrophages. J. Invest. Dermatol. 128(9), 2225-2231 (2008).
79. Bursch LS, Wang L, Igyarto B et al. Identification of a novel population of Langerin+ dendritic cells. J. Exp. Med. 204(13), 3147-3156 (2007).
80. Ginhoux F, Collin MP, Bogunovic M et al. Blood-derived dermal langerin+ dendritic cells survey the skin in the steady state. J. Exp. Med. 204(13), 3133-3146 (2007).
81. Poulin LF, Henri S, de BB et al. The dermis contains langerin+ dendritic cells that develop and function independently of epidermal Langerhans cells. J. Exp. Med. 204(13), 3119-3131 (2007).
82. Merad M, Ginhoux F, Collin M. Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells. Nat. Rev. Immunol. 8(12), 935-947 (2008).
83. Guilliams M, Crozat K, Henri S et al. Skin-draining lymph nodes contain dermis-derived CD103() dendritic cells that constitutively produce retinoic acid and induce Foxp3(+) regulatory T cells. Blood 115(10), 1958-1968 (2010).
84. Raverdeau M, Mills KH. Modulation of T cell and innate immune responses by retinoic Acid. J. Immunol. 192(7), 2953-2958 (2014).
85. Bonifaz L, Bonnyay D, Mahnke K et al. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J. Exp. Med. 196(12), 1627-1638 (2002).
86. Yu X, Chen T, Feg H et al. Oral abstract sessions: langerhans cells are crucial in the skin-induced tolerance to peanut. Allergy 69, 1-96 (2014).
87. Dioszeghy V, Mondoulet L, Dhelft V et al. The regulatory T cells induction by epicutaneous immunotherapy is sustained and mediates long-term protection from eosinophilic disorders in peanut-sensitized mice. Clin. Exp. Allergy 44(6), 867-881 (2014).
88. van Wijk WF, Hoeks S, Nierkens S et al. CTLA-4 signaling regulates the intensity of hypersensitivity responses to food antigens, but is not decisive in the induction of sensitization. J. Immunol. 174(1), 174-179 (2005).
89. Huehn J, Siegmund K, Lehmann JC et al. Developmental stage, phenotype, and migration distinguish naiveand effector/memory-like CD4+ regulatory T cells. J. Exp. Med. 199(3), 303-313 (2004).
90. Mondoulet L, Dioszeghy V, Puteaux E et al. Specific epicutaneous immunotherapy prevents sensitization to new allergens in a murine model. J. Allergy Clin. Immunol. 135(6), 1546-1557 (2015).
91. Tordesillas L, Mondoulet L, Benhamou PH et al. Epicutaneous but not oral immunotherapy induces antigenspecific gastrointestinal Tregs and protects against foodinduced anaphylaxis. J. Allergy Clin. Immunol. 135(2), Abstract 226 (2015).
92. Dioszeghy V, Mondoulet L, Wavrin S et al. Larger and stronger expression of Tregs gut homing receptors with epicutaneous than with sublingual or oral immunotherapy. J. Allergy Clin. Immunol. 135(2), Abstract 159 (2015).
93. Tang Q, Bluestone JA. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat. Immunol. 9(3), 239-244 (2008).
94. Lui KO, Waldmann H, Fairchild PJ. Embryonic stem cells: overcoming the immunological barriers to cell replacement therapy. Curr. Stem Cell Res. Ther. 4(1), 70-80 (2009).
95. Mondoulet L, Tost J, Ligouis M et al. Epigenetic changes following epicutaneous immunotherapy in peanut sensitized mice. J. Allergy Clin. Immunol. 135(2), Abstract 143 (2015).